Augmenting antitumor immune responses with epigenetic modifying agents

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Héninger, Erika ^a   Krueger, Timothy E G ^a   Lang, Joshua M ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antigen presentation; Epigenetics; Histone acetylation; Methylation; Tumor immunotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CD28 ANTIGEN; CLADRIBINE; CLOFARABINE; CP 4200; CURCUMIN; CYTOSINE DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISULFIRAM; EPIGALLOCATECHIN GALLATE; EQUOL; FLUDARABINE; GENISTEIN; HYDRALAZINE; IM25; N PHTHALOYLTRYPTOPHAN; NANAOMYCIN A; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PANOBINOSTAT; PARTHENOLIDE; PROCAINAMIDE; PROCAINE; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; RESVERATROL; SGI 110; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZEBULARINE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER THERAPY; CELL FUNCTION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; REVIEW; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT;

EID: 84926617120     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00029     Document Type: Review

References (179)

1. Wang X, Gao H, Ren L, Gu J, Zhang Y, Zhang Y. Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer. BMC Cancer (2014) 14:308. doi:10.1186/1471-2407-14-308
2. Cheng X, Blumenthal RM. Mammalian DNA methyltransferases: a structural perspective. Structure (2008) 16:341-50. doi:10.1016/j.str.2008.01.004
3. Cross SH, Bird AP. CpG islands and genes. Curr Opin Genet Dev (1995) 5:309-14. doi:10.1016/0959-437X(95)80044-1
4. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 16:168-74. doi:10.1016/S0168-9525(99)01971-X
5. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer (2004) 4:143-53. doi:10.1038/nrc1279
6. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature (1993) 366:362-5. doi:10.1038/366362a0
7. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 10:687-92. doi:10.1093/hmg/10.7.687
8. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet (2008) 9:465-76. doi:10.1038/nrg2341
9. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 20:85-93. doi:10.1016/0092-8674(80)90237-8
10. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene (2002) 21:5483-95. doi:10.1038/sj.onc.1205699
11. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res (2007) 67:6400-8. doi:10.1158/0008-5472.CAN-07-0251
12. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol (2002) 321:591-9. doi:10.1016/S0022-2836(02)00676-9
13. Brueckner B, Rius M, Markelova MR, Fichtner I, Hals PA, Sandvold ML, et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther (2010) 9:1256-64. doi:10.1158/1535-7163.MCT-09-1202
14. Pettitt AR. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol (2003) 121:692-702. doi:10.1046/j.1365-2141.2003.04336.x
15. Jeha S, Gandhi V, Chan KW, Mcdonald L, Ramirez I, Madden R, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 103:784-9. doi:10.1182/blood-2003-06-2122
16. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol (1988) 140:2197-200.
17. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res (2003) 63:4984-9.
18. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res (2009) 15:6070-8. doi:10.1158/1078-0432.CCR-09-1035
19. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res (2005) 65:6305-11. doi:10.1158/0008-5472.CAN-04-2957
20. Lin YS, Shaw AY, Wang SG, Hsu CC, Teng IW, Tseng MJ, et al. Identification of novel DNA methylation inhibitors via a two-component reporter gene system. J Biomed Sci (2011) 18:3. doi:10.1186/1423-0127-18-3
21. Kuck D, Caulfield T, Lyko F, Medina-Franco JL. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther (2010) 9:3015-23. doi:10.1158/1535-7163.MCT-10-0609
22. Majid S, Dar AA, Shahryari V, Hirata H, Ahmad A, Saini S, et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-cell translocation gene 3 in prostate cancer. Cancer (2010) 116:66-76. doi:10.1002/cncr.24662
23. Bosviel R, Durif J, Dechelotte P, Bignon YJ, Bernard-Gallon D. Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines. Br J Nutr (2012) 108:1187-93. doi:10.1017/S000711451100657X
24. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett (2009) 19:706-9. doi:10.1016/j.bmcl.2008.12.041
25. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol (2005) 68:1018-30. doi:10.1124/mol.104.008367
26. Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 109:7765-9. doi:10.1073/pnas.1205132109
27. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, et al. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther (2009) 329:505-14. doi:10.1124/jpet.108.147934
28. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia (1964) 20:202-3. doi:10.1007/BF02135399
29. Sorm F, Vesely J. Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma (1968) 15:339-43.
30. Momparler RL, Onetto-Pothier N, Momparler LF. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype. Leuk Res (1990) 14:755-60. doi:10.1016/0145-2126(90)90068-K
31. Fialova B, Smesny Trtkova K, Paskova L, Langova K, Kolar Z. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines. Oncol Rep (2013) 29:2039-45. doi:10.3892/or.2013.2344
32. Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, et al. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate (2010) 70:1166-78. doi:10.1002/pros.21151
33. Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, et al. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 9:1443-50. doi:10.1158/1535-7163.MCT-09-1048
34. Marquez VE, Barchi JJ Jr, Kelley JA, Rao KV, Agbaria R, Ben-Kasus T, et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids (2005) 24:305-18. doi:10.1081/NCN-200059765
35. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat (2010) 120:581-92. doi:10.1007/s10549-009-0420-3
36. Yang PM, Lin YT, Shun CT, Lin SH, Wei TT, Chuang SH, et al. Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress. Sci Rep (2013) 3:3219. doi:10.1038/srep03219
37. Candelaria M, De La Cruz-Hernandez E, Taja-Chayeb L, Perez-Cardenas E, Trejo-Becerril C, Gonzalez-Fierro A, et al. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One (2012) 7:e29181. doi:10.1371/journal.pone.0029181
38. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, et al. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas-and NK cell-mediated cell death. Int J Oncol (2012) 41:83-91. doi:10.3892/ijo.2012.1438
39. Graca I, Sousa EJ, Costa-Pinheiro P, Vieira FQ, Torres-Ferreira J, Martins MG, et al. Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget (2014) 5:5950-64.
40. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem (2005) 280:40749-56. doi:10.1074/jbc.M505593200
41. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res (2003) 9:1596-603.
42. Halby L, Champion C, Senamaud-Beaufort C, Ajjan S, Drujon T, Rajavelu A, et al. Rapid synthesis of new DNMT inhibitors derivatives of procainamide. Chembiochem (2012) 13:157-65. doi:10.1002/cbic.201100522
43. Herbst A, Rahmig K, Stieber P, Philipp A, Jung A, Ofner A, et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol (2011) 106:1110-8. doi:10.1038/ajg.2011.6
44. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer (2008) 123:552-60. doi:10.1002/ijc.23590
45. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2005) 11:77-84. doi:10.1038/nm1161
46. Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One (2013) 8:e79781. doi:10.1371/journal.pone.0079781
47. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer (2011) 117:4424-38. doi:10.1002/cncr.26073
48. Chiao MT, Cheng WY, Yang YC, Shen CC, Ko JL. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy (2013) 9:1509-26. doi:10.4161/auto.25664
49. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene (2004) 23:6261-71. doi:10.1038/sj.onc.1207830
50. Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer (2006) 119:221-8. doi:10.1002/ijc.21824
51. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med (2007) 9:440-51. doi:10.1002/jgm.1036
52. Carlisi D, Lauricella M, D'anneo A, Emanuele S, Angileri L, Di Fazio P, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer (2009) 45:2425-38. doi:10.1016/j.ejca.2009.06.024
53. Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie (2012) 94:287-99. doi:10.1016/j.biochi.2011.06.031
54. Jazirehi AR, Arle D. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 2:55-74.
55. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood (2009) 114:380-93. doi:10.1182/blood-2008-10-182758
56. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res (2013) 23(5):341-8. doi:10.1097/CMR.0b013e328364c0ed
57. Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res (2011) 71:454-62. doi:10.1158/0008-5472.CAN-10-3184
58. Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer (2014) 135:2223-31. doi:10.1002/ijc.28865
59. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the department of defense prostate cancer clinical trial consortium and University of Chicago phase 2 consortium. Cancer (2009) 115:5541-9. doi:10.1002/cncr.24597
60. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett (2009) 280:233-41. doi:10.1016/j.canlet.2009.02.019
61. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 2:721-8.
62. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther (2006) 5:1309-17. doi:10.1158/1535-7163.MCT-05-0442
63. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2005) 11:1-15. doi:10.2119/2006-00005.Dinarello
64. Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol (2010) 149:518-28. doi:10.1111/j.1365-2141.2010.08124.x
65. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res (2009) 15:6841-51. doi:10.1158/1078-0432.CCR-09-0547
66. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther (2010) 9:642-52. doi:10.1158/1535-7163.MCT-09-0689
67. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood (2003) 102:2615-22. doi:10.1182/blood-2003-01-0233
68. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res (2001) 7:962-70.
69. Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrim idine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem (2010) 53:8663-78. doi:10.1021/jm101177s
70. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 5:769-84. doi:10.1038/nrd2133
71. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays (1995) 17:423-30. doi:10.1002/bies.950170510
72. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18:2461-70. doi:10.1038/sj.onc.1202564
73. Duong V, Bret C, Altucci L, Mai A, Duraffourd C, Loubersac J, et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res (2008) 6:1908-19. doi:10.1158/1541-7786.MCR-08-0299
74. Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A (2010) 107:20003-8. doi:10.1073/pnas.1013754107
75. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia (2008) 22:1026-34. doi:10.1038/leu.2008.9
76. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Anticancer Res (2006) 26:939-45.
77. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther (2003) 2:401-8.
78. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther (2008) 7:759-68. doi:10.1158/1535-7163.MCT-07-2026
79. Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol (2012) 69:901-9. doi:10.1007/s00280-011-1766-x
80. Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol (2006) 549:9-18. doi:10.1016/j.ejphar.2006.08.010
81. Yeung A, Bhargava RK, Ahn R, Bahna S, Kang NH, Lacoul A, et al. HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation. Biomed Pharmacother (2012) 66:232-6. doi:10.1016/j.biopha.2011.06.007
82. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 20:6969-78. doi:10.1093/emboj/20.24.6969
83. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr (2003) 133:2485S-93S.
84. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell (1978) 14:105-13. doi:10.1016/0092-8674(78)90305-7
85. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) (1994) 47:301-10. doi:10.7164/antibiotics.47.301
86. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem (1993) 268:22429-35.
87. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res (2000) 60:6068-74.
88. Peled T, Shoham H, Aschengrau D, Yackoubov D, Frei G, Rosenheimer GN, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol (2012) 40(342-355):e341. doi:10.1016/j.exphem.2011.12.005
89. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A (2001) 98:15113-8. doi:10.1073/pnas.261574398
90. Napper AD, Hixon J, Mcdonagh T, Keavey K, Pons JF, Barker J, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem (2005) 48:8045-54. doi:10.1021/jm050522v
91. Olaharski AJ, Rine J, Marshall BL, Babiarz J, Zhang L, Verdin E, et al. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet (2005) 1:e77. doi:10.1371/journal.pgen.0010077
92. McCarthy AR, Sachweh MC, Higgins M, Campbell J, Drummond CJ, Van Leeuwen IM, et al. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol Cancer Ther (2013) 12:352-60. doi:10.1158/1535-7163.MCT-12-0900
93. Rotili D, Tarantino D, Nebbioso A, Paolini C, Huidobro C, Lara E, et al. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem (2012) 55:10937-47. doi:10.1021/jm3011614
94. Hoffmann G, Breitenbucher F, Schuler M, Ehrenhofer-Murray AE. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem (2014) 289:5208-16. doi:10.1074/jbc.M113.487736
95. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res (2006) 66:4368-77. doi:10.1158/0008-5472.CAN-05-3617
96. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem (2001) 276:38837-43. doi:10.1074/jbc.M106779200
97. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, et al. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2009) 28:781-91. doi:10.1038/onc.2008.436
98. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 13:454-63. doi:10.1016/j.ccr.2008.03.004
99. Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol (2013) 9:319-25. doi:10.1038/nchembio.1223
100. Kim DH, Shin J, Kwon HJ. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp Mol Med (2007) 39:47-55. doi:10.1038/emm.2007.6
101. Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem (2012) 55:9891-9. doi:10.1021/jm301098e
102. Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One (2013) 8:e68915. doi:10.1371/journal.pone.0068915
103. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res (2003) 63:3637-45.
104. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer (2000) 83:817-25. doi:10.1054/bjoc.2000.1327
105. Wang J, Kim TH, Ahn MY, Lee J, Jung JH, Choi WS, et al. Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol (2012) 41:1101-9. doi:10.3892/ijo.2012.1534
106. Quagliana JM, O'bryan RM, Baker L, Gottlieb J, Morrison FS, Eyre HJ, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep (1977) 61:51-4.
107. Reed MD, Tellez CS, Grimes MJ, Picchi MA, Tessema M, Cheng YS, et al. Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer (2013) 109:1775-81. doi:10.1038/bjc.2013.575
108. Naldi I, Taranta M, Gherardini L, Pelosi G, Viglione F, Grimaldi S, et al. Novel epigenetic target therapy for prostate cancer: a preclinical study. PLoS One (2014) 9:e98101. doi:10.1371/journal.pone.0098101
109. Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood (2011) 118:1472-80. doi:10.1182/blood-2010-11-320093
110. Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, Reis IM. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin Genitourin Cancer (2015) 13(1):22-31. doi:10.1016/j.clgc.2014.07.008
111. Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol (2007) 18:1529-38. doi:10.1093/annonc/mdm204
112. Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol (2014) 74:691-7. doi:10.1007/s00280-014-2501-1
113. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, De La Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One (2006) 1:e98. doi:10.1371/journal.pone.0000098
114. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer (2012) 12:465-77. doi:10.1038/nrc3256
115. Gross L. The importance of dosage in the intradermal immunization against transplantable neoplasms. Cancer Res (1943) 3:770-8.
116. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med (2004) 199:155-66. doi:10.1084/jem.20031677
117. Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, et al. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J Immunol (2012) 188:111-21. doi:10.4049/jimmunol.1002612
118. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 105:20422-7. doi:10.1073/pnas.0810777105
119. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res (2008) 14:3283-90. doi:10.1158/1078-0432.CCR-07-5279
120. Kalejs M, Erenpreisa J. Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int (2005) 5:4. doi:10.1186/1475-2867-5-4
121. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 5:615-25. doi:10.1038/nrc1669
122. Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol (2014) 54:251-72. doi:10.1146/annurev-pharmtox-011112-140326
123. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, et al. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 70:1778-87. doi:10.1002/pros.21214
124. Smith HA, Cronk RJ, Lang JM, Mcneel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res (2011) 71:6785-95. doi:10.1158/0008-5472.CAN-11-2127
125. Freitas M, Malheiros S, Stavale JN, Biassi TP, Zamuner FT, De Souza Begnami M, et al. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget (2013) 4:636-46.
126. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 67:1781-90. doi:10.1002/pros.20665
127. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van Den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643-7. doi:10.1126/science.1840703
128. Boon T, Cerottini JC, Van Den Eynde B, Van Der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 12:337-65. doi:10.1146/annurev.iy.12.040194.002005
129. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res (1994) 54:1766-71.
130. Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, et al. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One (2014) 9:e93321. doi:10.1371/journal.pone.0093321
131. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene (2002) 21:5496-503. doi:10.1038/sj.onc.1205602
132. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 93:7149-53. doi:10.1073/pnas.93.14.7149
133. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer (2002) 2:29. doi:10.1186/1471-2407-2-29
134. Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer (2004) 4:65. doi:10.1186/1471-2407-4-65
135. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene (2006) 25:6975-85. doi:10.1038/sj.onc.1209678
136. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res (2011) 71:4192-204. doi:10.1158/0008-5472.CAN-10-2442
137. Loriot A, De Plaen E, Boon T, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem (2006) 281:10118-26. doi:10.1074/jbc.M510469200
138. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer (2008) 122:2542-53. doi:10.1002/ijc.23407
139. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jager E, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res (2010) 34:899-905. doi:10.1016/j.leukres.2010.02.004
140. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 5:587-98.
141. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother (2001) 24:151-61. doi:10.1097/00002371-200103000-00010
142. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg (2001) 71:295-301. doi:10.1016/S0003-4975(00)02421-8
143. Toor AA, Payne KK, Chung HM, Sabo RT, Hazlett AF, Kmieciak M, et al. Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. Br J Haematol (2012) 158:700-11. doi:10.1111/j.1365-2141.2012.09225.x
144. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 36:133-51. doi:10.1097/CJI.0b013e3182829903
145. Kortenhorst MS, Wissing MD, Rodriguez R, Kachhap SK, Jans JJ, Van Der Groep P, et al. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics (2013) 8:907-20. doi:10.4161/epi.25574
146. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (2006) 118:6-10. doi:10.1002/ijc.21303
147. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother (2010) 59:465-72. doi:10.1007/s00262-009-0765-9
148. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother (2010) 59:529-40. doi:10.1007/s00262-009-0769-5
149. Ayshamgul H, Ma H, Ilyar S, Zhang LW, Abulizi A. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl) (2011) 124:341-6.
150. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst (2013) 105:1172-87. doi:10.1093/jnci/djt184
151. Procko E, Gaudet R. Antigen processing and presentation: TAPping into ABC transporters. Curr Opin Immunol (2009) 21:84-91. doi:10.1016/j.coi.2009.02.003
152. Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell (2011) 20:728-40. doi:10.1016/j.ccr.2011.11.006
153. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget (2013) 4:2067-79.
154. Setiadi AF, David MD, Seipp RP, Hartikainen JA, Gopaul R, Jefferies WA. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol (2007) 27:7886-94. doi:10.1128/MCB.01547-07
155. Simova J, Pollakova V, Indrova M, Mikyskova R, Bieblova J, Stepanek I, et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Br J Cancer (2011) 105:1533-41. doi:10.1038/bjc.2011.428
156. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med (2012) 271:183-92. doi:10.1111/j.1365-2796.2011.02496.x
157. Dilek N, Poirier N, Hulin P, Coulon F, Mary C, Ville S, et al. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One (2013) 8:e83139. doi:10.1371/journal.pone.0083139
158. Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, Xu YH, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One (2013) 8:e62924. doi:10.1371/journal.pone.0062924
159. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A (2014) 111:11774-9. doi:10.1073/pnas.1410626111
160. Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia (2014) 28:1280-8. doi:10.1038/leu.2013.355
161. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
162. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2013) 19:462-8. doi:10.1158/1078-0432.CCR-12-2625
163. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 20:5064-74. doi:10.1158/1078-0432.CCR-13-3271
164. West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res (2013) 73:7265-76. doi:10.1158/0008-5472.CAN-13-0890
165. West AC, Smyth MJ, Johnstone RW. The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology (2014) 3:e27414. doi:10.4161/onci.27414
166. Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S, et al. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol (2013) 54:296-301. doi:10.1016/j.molimm.2012.12.012
167. Xiao W, Dong W, Zhang C, Saren G, Geng P, Zhao H, et al. Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. Eur J Med Res (2013) 18:61. doi:10.1186/2047-783X-18-61
168. Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. J Immunother Cancer (2014) 2:8. doi:10.1186/2051-1426-2-8
169. Araki Y, Fann M, Wersto R, Weng NP. Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol (2008) 180:8102-8. doi:10.4049/jimmunol.180.12.8102
170. Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL, et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol (2009) 183:1695-704. doi:10.4049/jimmunol.0900592
171. Lal G, Zhang N, Van Der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol (2009) 182:259-73. doi:10.4049/jimmunol.182.1.259
172. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 69:8693-9. doi:10.1158/0008-5472.CAN-09-1456
173. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 13:6947-58. doi:10.1158/1078-0432.CCR-07-0842
174. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 14:1032-40. doi:10.1158/1078-0432.CCR-07-2056
175. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urol Oncol (2011) 29(6):682-9. doi:10.1016/j.urolonc.2009.09.015
176. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, et al. A phase II study of 5-aza-2'-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori (1998) 84:87-9.
177. Deborah B, Dana R, Rodney D, Walter MS, Glenn L, David CS, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer (2009) 115:5541-9. doi:10.1002/cncr.24597
178. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 25:883-7. doi:10.1089/aid.2008.0294
179. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy a case series report. Haematologica (2009) 94:1618-22. doi:10.3324/haematol.2009.008607